Stockreport

Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association [Yahoo! Finance]

Keros Therapeutics, Inc. - common stock  (KROS) 
PDF Durable clinical responses were associated with improvements in patient-reported measures of fatigue Data from ongoing Phase 2 clinical trial in myelofibrosis continu [Read more]